Skip to main content

Table 1 The general clinical data of patients

From: Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer

Information

CAPE-OX-CRT group, n = 30 (%)

Control group

n = 26 (%)

P

Age (years)

 Median age

58

58

 

 Range

27–72

24–73

 

Gender

0.432

 Male

13 (43.33)

14 (53.8)

 

 Female

17 (56.67)

12 (46.2)

 

KPS score

0.240

 70

2 (6)

1 (3.85)

 

 80

22 (74)

20 (76.92)

 

 90

6 (20)

5 (19.23)

 

Postoperative staging

0.890

 II

11 (36.67)

10 (38.46)

 

 III

19 (63.33)

16 (61.54)

 

Postoperative T staging

0.096

 T2

4 (13.33)

4 (15.38)

 

 T3

11 (36.67)

9 (34.62)

 

 T4a

12 (40)

10 (38.46)

 

 T4b

3 (10)

3 (11.54)

 

Postoperative N staging

0.437

 N0

5 (16.67)

6 (23.08)

 

 N1

16 (53.33)

12 (46.15)

 

 N2

9 (30)

8 (30.77)